1月13日，博安生物发布公告，其自主研发的地舒单抗注射液(60mg)(代号BA6101)已获玻利维亚国家药 品和卫生技术局(AGEMED)批准上市。BA6101为原研参照药Prolia的生物类似药，在全球范围内Prolia 广泛应用于骨质疏松症的治疗。 香港联交所最新资料显示，1月13日，博安生物(06955)股东将股票由中国证券登记结算香港转入中信证 券经纪香港，转仓市值5.12亿港元，占比8.76%。 ...

每经AI快讯，博安生物(06955.HK)涨超6%，截至发稿涨6.28%，报9.98港元，成交额4988.45万港元。 （文章来源：每日经济新闻） ...

Core Viewpoint - The company Boan Biotechnology (06955) has announced that its self-developed drug BA6101 has received approval for market launch in Bolivia, which is a biosimilar to the reference drug Prolia® used for osteoporosis treatment [1][6]. Group 1: Stock Performance - Boan Biotechnology's stock price increased by 6.07%, currently trading at 9.96 HKD, with a trading volume of 54.81 million HKD [1][6]. Group 2: Product Approval - The Bolivian National Medicines and Health Technologies Agency (AGEMED) has approved the injection of BA6101 (60mg) for market launch [1][6]. - BA6101 is a biosimilar to Prolia®, which is widely used globally for the treatment of osteoporosis, and it shares the same indications as the reference drug [1][6]. Group 3: Global Development Strategy - BA6101 is developed based on the company's global research and development strategy, with plans for commercialization in multiple countries and regions [1][6]. - The company is currently in the approval process for BA6101's marketing authorization in the UK and plans to submit applications in Europe, the United States, Japan, and other regions [1][6].

消息面上，1月11日，博安生物发布公告，公司董事会欣然宣布，其自主研发的地舒单抗注射液(60mg) (代号BA6101)已获玻利维亚国家药品和卫生技术局(AGEMED)批准上市。BA6101为原研参照药Prolia的 生物类似药，在全球范围内Prolia广泛应用于骨质疏松症的治疗。BA6101的适应症与原研参照药相同。 BA6101基于本公司全球研发策略开发，并计划在全球多个国家及地区开展商业化。当前，BA6101在英 国的上市许可申请正处于审批阶段，本公司计划在欧洲、美国、日本等国家和地区提交上市许可申请。 智通财经APP获悉，博安生物(06955)涨超6%，截至发稿，涨6.28%，报9.98港元，成交额4988.45万港 元。 ...

博安生物(06955)涨超6%，截至发稿，涨6.28%，报9.98港元，成交额4988.45万港元。 消息面上，1月11日，博安生物发布公告，公司董事会欣然宣布，其自主研发的地舒单抗注射液(60mg) (代号BA6101)已获玻利维亚国家药品和卫生技术局(AGEMED)批准上市。BA6101为原研参照药Prolia的 生物类似药，在全球范围内Prolia广泛应用于骨质疏松症的治疗。BA6101的适应症与原研参照药相同。 BA6101基于本公司全球研发策略开发，并计划在全球多个国家及地区开展商业化。当前，BA6101在英 国的上市许可申请正处于审批阶段，本公司计划在欧洲、美国、日本等国家和地区提交上市许可申请。 ...

Summary of Key Points Core Viewpoint - The latest shareholder equity disclosures for several companies, including Zhongjia Guoxin, Boan Biotech, Fudan Zhangjiang, and others, were made on January 12, 2026, indicating significant changes in shareholdings among various institutional investors [1]. Group 1: Zhongjia Guoxin (00899) - Jiang Xiaojun increased holdings from 5.60 million shares to 16.80 million shares, representing a holding percentage of 3.77% [2] - Li Jiayi raised holdings from 23.39 million shares to 70.18 million shares, with a holding percentage of 15.76% [2] - Lin Bilin increased holdings from 0.10 million shares to 31.30 million shares, now holding 7.03% [2] - FULL TENDA DEVELOPMENT increased holdings from 23.88 million shares to 71.65 million shares, holding 16.09% [2] - GREEN DEER HOLDINGS LIMITED increased holdings from 0.10 million shares to 31.30 million shares, now holding 7.03% [2] - Yao Jigen increased holdings from 24.96 million shares to 74.88 million shares, with a holding percentage of 16.82% [2] Group 2: Boan Biotech (06955) - Yantai Green Leaf Pharmaceutical Holdings reduced holdings from 361 million shares to 311 million shares, now holding 49.90% [2] - Luye Geneora Holding Limited acquired 50 million shares, holding 8.03% [2] - AsiaPharm Investments reduced holdings from 361 million shares to 311 million shares, now holding 49.90% [2] - Shandong Green Leaf Pharmaceutical reduced holdings from 361 million shares to 311 million shares, now holding 49.90% [2] - Luye Pharma Hong Kong Limited reduced holdings from 361 million shares to 311 million shares, now holding 49.90% [2] Group 3: Other Companies - Fudan Zhangjiang (01349): Yang Zongmeng reduced holdings from 59.33 million shares to 55.79 million shares, now holding 7.85% [2] - Prosperity Industrial Trust (00778): ESR Asset Management increased holdings from 76.05 million shares to 80.57 million shares, now holding 3.92% [2] - Shishi Pharmaceutical Group (02005): Qu Jiguang maintained holdings at 1.233 billion shares, holding 41.79% [2] - Zheli Holdings (02209): Lei Baicheng slightly reduced holdings from 31.31 million shares to 31.05 million shares, now holding 7.43% [2]

Core Viewpoint - The company has announced an increase in trading volume of its H-shares on January 9, 2026, and confirmed no knowledge of any reasons for this change, aside from disclosed information regarding the issuance of exchangeable preferred shares by its controlling shareholder, Luye Pharma Group [1][2] Group 1: Share Issuance and Trading - Luye Pharma Group's wholly-owned subsidiary, Luye Geneora Holding Limited, issued exchangeable preferred shares on December 12, 2025, which can be exchanged for 100.5 million H-shares held by Luye Pharma Group [1][2] - To comply with the agreement related to the exchangeable preferred shares, Luye Pharma Group arranged for its subsidiary, Shandong Luye Pharmaceutical Co., Ltd., to transfer 50 million H-shares to the issuer on the market [1] Group 2: Product Development and Approval - The company announced that its self-developed drug, BA6101 (60mg), has been approved for marketing by Bolivia's National Medicines and Health Technologies Authority (AGEMED) [2] - BA6101 is a biosimilar to the reference drug Prolia, widely used for the treatment of osteoporosis, and shares the same indications as the reference drug [2][3] - The development of BA6101 adhered to international guidelines, confirming its overall similarity to the reference drug in terms of quality, safety, and efficacy [3] Group 3: Commercialization Strategy - The company plans to commercialize BA6101 in Bolivia and has established strategic partnerships for its commercialization in other Latin American markets, the United States, Southeast Asia, Hong Kong, and Macau [3] - The company aims to accelerate its international strategy by providing high-quality domestic biopharmaceuticals, including BA6101, to meet global patient treatment needs [3]

Core Viewpoint - The company, Luye Pharma Group, has announced an increase in trading volume of its H-shares and confirmed that it is unaware of any reasons for this change, aside from disclosed information regarding the issuance of exchangeable preferred shares [1][2]. Group 1: Share Issuance and Trading - Luye Pharma Group's wholly-owned subsidiary, Luye Geneora Holding Limited, issued exchangeable preferred shares on December 12, 2025, which allow holders to exchange these shares for existing H-shares held by Luye Pharma Group [1][2]. - Following the issuance of the exchangeable preferred shares, an agreement was made to transfer 100.5 million H-shares to a designated custody account to fulfill the exchange rights associated with these shares [2]. - On January 9, 2026, Luye Pharma Group arranged for its subsidiary, Shandong Luye Pharmaceutical Co., Ltd., to transfer 50 million H-shares to the issuer in the market [2]. Group 2: Product Development and Approval - The company's self-developed drug, BA6101 (60mg), has been approved for market launch by Bolivia's National Medicines and Health Technologies Authority (AGEMED) [2][3]. - BA6101 is a biosimilar to the reference drug Prolia®, widely used for the treatment of osteoporosis, and has the same indications as the reference drug [3]. - The development of BA6101 adheres to international guidelines and has demonstrated high similarity in quality, safety, and efficacy compared to the reference drug, with no clinically significant differences [3]. Group 3: Commercialization Strategy - The company plans to commercialize BA6101 in Bolivia and enhance the accessibility of the drug for patients, providing more treatment options [4]. - Strategic partnerships have been established for the commercialization of BA6101 in other Latin American markets, the United States, Southeast Asia, Hong Kong, and Macau [4]. - The company aims to accelerate its international strategy by offering high-quality domestic biopharmaceuticals, including BA6101, to meet global patient treatment needs [4].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 的全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責 任。 本公司董事會（「董事會」）注意到本公司股份（「H股」）於2026年1月9日的成 交 量 有 所 上 升。經 就 本 公 司 作 出 在 有 關 情 況 下 屬 合 理 之 查 詢 後，董 事 會 確 認，除 下 文 所 披 露 者 外，其 並 不 知 悉(i)任 何 導 致 該 等 成 交 量 變 動 的 原 因； (ii)任 何 須 公 佈 以 避 免 本 公 司 證 券 出 現 虛 假 市 場 的 資 料；或(iii)任何根據香 港法例第571章證券及期貨條例第XIVA部 須 予 披 露 的 內 幕 消 息。 董事會已獲其控股股東綠葉製藥集團有限公司（「綠葉製藥」，連 同 其 附 屬 公司統稱「綠葉製藥集團」）通 知，於2025年12月12日，綠 葉 製 藥 的 全 資 附 屬 公 司Luye Geneora Holding Limited ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 山東博安生物技術股份有限公司 呈交日期: 2026年1月6日 因本公司是於中華人民共和國註冊成立的公司，「法定股本」之概念不適用於本公司，在上述「法定/註冊股本」部分顯示的資料是指本公司的註冊股本 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06955 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 622,333,694 | RMB | | 1 RMB | | 622,333,694 | | 增加 / 減少 (-) | | | 0 | | ...